- Home
- OPTN vs INMB Comparison
OPTN vs INMB Comparison
Compare OPTN & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- INMB
- Stock Information
- Founded
- OPTN 2010
- INMB 2015
- Country
- OPTN United States
- INMB United States
- Employees
- OPTN N/A
- INMB N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- OPTN Health Care
- INMB Health Care
- Exchange
- OPTN Nasdaq
- INMB Nasdaq
- Market Cap
- OPTN 117.6M
- INMB 123.0M
- IPO Year
- OPTN 2017
- INMB 2019
- Fundamental
- Price
- OPTN $0.71
- INMB $5.46
- Analyst Decision
- OPTN Strong Buy
- INMB Buy
- Analyst Count
- OPTN 2
- INMB 1
- Target Price
- OPTN $4.00
- INMB $22.00
- AVG Volume (30 Days)
- OPTN 516.5K
- INMB 357.5K
- Earning Date
- OPTN 11-07-2024
- INMB 10-30-2024
- Dividend Yield
- OPTN N/A
- INMB N/A
- EPS Growth
- OPTN N/A
- INMB N/A
- EPS
- OPTN N/A
- INMB N/A
- Revenue
- OPTN $75,058,000.00
- INMB $85,000.00
- Revenue This Year
- OPTN $24.44
- INMB N/A
- Revenue Next Year
- OPTN $49.00
- INMB N/A
- P/E Ratio
- OPTN N/A
- INMB N/A
- Revenue Growth
- OPTN 3.91
- INMB N/A
- 52 Week Low
- OPTN $0.65
- INMB $4.81
- 52 Week High
- OPTN $2.10
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- OPTN 33.40
- INMB 44.41
- Support Level
- OPTN $0.65
- INMB $5.09
- Resistance Level
- OPTN $0.70
- INMB $5.73
- Average True Range (ATR)
- OPTN 0.05
- INMB 0.32
- MACD
- OPTN -0.00
- INMB 0.09
- Stochastic Oscillator
- OPTN 24.67
- INMB 69.52
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.